{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"24.0","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"PFS was defined as the duration from the date of the first study drug dose to the disease progression or death, whichever occurs first. PD was defined using the IWC 2014 criteria, as any new lesion or an individual node/lesion must be abnormal with: \"LDi \\>1.5 cm\" and \"increase by 50% from perpendicular diameters nadir\" and \"an increase in LDi or shortest axis perpendicular to the LDi from nadir, 0.5 cm for lesions \\<2 cm or 1.0 cm for lesions \\>2 cm\".","dispersionType":"95% Confidence Interval","groups":[{"description":"HBI-8000 Tablets","id":"OG000","title":"HBI-8000"}],"paramType":"MEDIAN","populationDescription":"PPS","reportingStatus":"POSTED","timeFrame":"Up to approximately 47 months.","title":"Median Duration of Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}